Neurocrine Biosciences Appoints Dr. Eiry Roberts as CMO Following Dr. Sanjay Keswani's Departure
NEUROCRINE BIOSCIENCES INC
Subscribe to track NBIX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
### Neurocrine Biosciences (NASDAQ: NBIX) Form 8-K Summary
**Item 5.02 - Leadership Transition**
- **Executive Appointment:** Dr. Eiry W. Roberts appointed as Chief Medical Officer, effective September 28, 2026.
- **Executive Departure:** Dr. Sanjay Keswani stepped down as Chief Medical Officer by mutual agreement, effective September 25, 2026.
- **Incoming CMO Compensation:**
- Base Salary: $825,000
- Target Cash Bonus: 60% of base pay earned for 2026
- Equity Grants (Target Value $1,250,000 total): $625,000 Stock Options, $250,000 RSUs, $375,000 PSUs
- **Severance:** Dr. Keswani is entitled to severance benefits under Section 4.1 of the Executive Severance Plan.
Comprehensive Analysis
Executive Transition Summary
On September 28, 2026, the Board of Directors of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) appointed Dr. Eiry W. Roberts, M.D. as Chief Medical Officer, effective September 28, 2026. Dr. Roberts succeeds Dr. Sanjay Keswani, M.D., whose service terminated by mutual agreement on September 25, 2026.
Key Terms of Dr. Roberts' Employment Agreement
- Base Salary: $825,000 per annum.
- Annual Target Bonus: 60% of earned base salary for calendar year 2026.
- Equity Incentive Grants: Total target value of approximately $1,250,000, to be granted two business days post-filing of the first subsequent Form 10-Q:
- Stock Options: ~$625,000 grant value, vesting monthly over a four-year period.
- Restricted Stock Units (RSUs): ~$250,000 grant value, vesting annually over four years.
- Performance-Vesting RSUs (PSUs): ~$375,000 grant value, vesting according to the February 2026 executive PSU terms.
- Severance & Prior Awards: Entitled to standard coverage under the Company's Executive Severance Plan; existing equity awards remain outstanding and continue vesting according to their original terms.
Departing Executive Severance
Dr. Keswani will receive severance benefits in accordance with Section 4.1 of Neurocrine's Executive Severance Plan (effective February 7, 2025), subject to standard terms and conditions.
Market Impact & Analysis
This filing reflects an orderly transition of executive clinical leadership. The compensation package aligns with standard biopharmaceutical industry executive norms and does not include open-market purchases or dispositions.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.